954 On Other Exchanges
Symbol
Exchange
Berlin
Hong Kong

changmao biochemical engin-h (954) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHANGMAO BIOCHEMICAL ENGIN-H (954)
\

Related News

No related news articles were found.

changmao biochemical engin-h (954) Related Businessweek News

No Related Businessweek News Found

changmao biochemical engin-h (954) Details

Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame; and animal feeds additives and pharmaceutical adjuvants and active pharmaceutical ingredients. The company is also involved in the research and development of medicine and nutraceutical products; production and sales of food additives; trading of organic acids; and property holding activities. In addition, it exports its products to Japan, Europe, Australia, the United States, and the Middle East. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.

479 Employees
Last Reported Date: 03/21/19
Founded in 1992

changmao biochemical engin-h (954) Top Compensated Officers

CEO, GM & Executive Director
Total Annual Compensation: CNY1.1M
Chairman & Compliance Officer
Total Annual Compensation: CNY2.0M
Compensation as of Fiscal Year 2018.
changmao biochemical engin-h
Changmao Biochemical Engineering Company Limited Announces Consolidated Earnings Results for the Year Ended 31 December 2018

Changmao Biochemical Engineering Company Limited announced consolidated earnings results for the year ended 31 December 2018. For the year, the company's reported revenue was RMB 639,120,000 compared to RMB 630,841,000 for the same period a year ago. Operating profit was RMB 55,454,000 compared to RMB 1,215,000 for the same period a year ago. Profit for the year was RMB 49,909,000 compared to RMB 2,700,000 for the same period a year ago. Basic earnings per share for profit attributable to equity holders of the company was RMB 0.095 compared to RMB 0.006 for the same period a year ago.

Changmao Biochemical Engineering Company Limited Recommends Final Dividend for the Year Ended December 31, 2018, Payable on July 31, 2019

Changmao Biochemical Engineering Company Limited's directors recommend the payment of a final dividend of RMB 0.05 (inclusive of tax) per share in cash, totalling approximately RMB 26,485,000 for the year ended 31 December 2018. The proposed dividend is subject to approval by the company's shareholders in the forthcoming annual general meeting. It is intended that the dividend will be payable on 31 July 2019 to the holders of Domestic Shares, Foreign Shares and H Shares whose names appear on the register of member of the company at 4:30 p.m. on 22 May 2019. Further information relating to the payment of the dividend will be made by the company in due course.

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 10, 2019

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 10, 2019, at 10:00 China Standard Time. Location: Capital Conference Services Limited, Suite 2418, 24/F, Jardine House, 1 Connaught Place Central Hong Kong Hong Kong Agenda: To receive the audited consolidated financial statements of the Company, together with the report of the Directors, the report of the Supervisory Committee and the international independent auditor's report for the year ended 31 December 2018; to receive the audited consolidated financial statements of the Company, together with the report of the Directors, the report of the Supervisory Committee and the international independent auditor's report for the year ended 31 December 2018; to consider and approve the appropriation to statutory common reserve for the year ended 31 December 2018; and to consider other matters.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

954 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 954.
View Industry Companies
 

Industry Analysis

954

Industry Average

Valuation 954 Industry Range
Price/Earnings 7.6x
Price/Sales 0.6x
Price/Book 0.6x
Price/Cash Flow 7.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHANGMAO BIOCHEMICAL ENGIN-H, please visit www.cmbec.com.hk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.